<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993876</url>
  </required_header>
  <id_info>
    <org_study_id>KO 2067</org_study_id>
    <nct_id>NCT00993876</nct_id>
  </id_info>
  <brief_title>Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment</brief_title>
  <acronym>Decoflex</acronym>
  <official_title>Cognitive Flexibility and Its Correlation to Sleep and Neuroplasticity In The Course Of Depression During Different Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zentrum für Integrative Psychiatrie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zentrum für Integrative Psychiatrie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive deficits in major depression seem explicable by the well-recognized concept of
      impaired neuroplasticity in mood disorders. This concept initially emerged from preclinical
      evidence that antidepressants phosphorylate and therefore activate the cyclic AMP response
      element binding protein (CREB) that is essential for synaptic plasticity. Nevertheless, the
      question remains whether the activation of CREB by antidepressants is relevant for the
      remission of cognitive deficits in patients. We addressed this issue by investigating the
      cognitive improvement during treatment with either citalopram or reboxetine because these
      antidepressants are different in their capacity to increase phosphorylated CREB (pCREB).
      Besides the pharmacological treatment groups, another group of patients was treated
      exclusively with psychotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We randomly assigned forty-five depressive patients to one of three treatment groups
      (Citalopram, Reboxetin or interpersonal psychotherapy (IPT)). At baseline, day 7 and day 28
      we assessed the severity of depression and the cognitive performance with respect to
      cognitive flexibility, memory and attention. We measured pCREB with an enzyme linked immuno
      sorbent assay (ELISA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cognitive performance with respect to cognitive flexibility, memory and attention</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CREB-phosphorylation in T-Lymphocytes</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Cognitive Performance in Major Depression</condition>
  <arm_group>
    <arm_group_label>Selective serotonin reuptake inhibitor (SSRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>citalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serotonin-norepinephrine reuptake inhibitor (SNRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>reboxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>interpersonal psychotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram</intervention_name>
    <description>20 to 30 mg per day for 4 weeks</description>
    <arm_group_label>Selective serotonin reuptake inhibitor (SSRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reboxetine</intervention_name>
    <description>4 to 8 mg per day for 4 weeks</description>
    <arm_group_label>Serotonin-norepinephrine reuptake inhibitor (SNRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>interpersonal psychotherapy</intervention_name>
    <arm_group_label>IPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed according DSM-IV criteria as suffering from major depressive disorder

          -  A baseline score of at least 18 in the Hamilton Depression Scale (HAMD)

          -  No psychopharmacological treatment at least one week prior inclusion or 3 days
             wash-out

        Exclusion Criteria:

          -  Severe depressive episode and/or psychotic depressive episode

        Axis I disorder:

          -  Substance-related Disorders

          -  Psychotic Disorders

          -  Dementia or other cognitive Disorders

          -  Obsessive-Compulsive Disorders

        Axis II disorder:

        • Borderline Personality Disorder

        Axis III disorder:

          -  Infectious Diseases

          -  Cancer

          -  Endocrinological Diseases

          -  Hematological Diseases

          -  Autoimmune Diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob M. Koch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zentrum für Integrative Psychiatrie, Kiel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Integrative Psychiatrie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>October 13, 2009</last_update_submitted>
  <last_update_submitted_qc>October 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2009</last_update_posted>
  <keyword>Depression</keyword>
  <keyword>CREB</keyword>
  <keyword>cognitive performance</keyword>
  <keyword>psychotherapy</keyword>
  <keyword>SSRI</keyword>
  <keyword>SNRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Reboxetine</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

